ANALYSIS OF THE USE OF VARIOUS ANTIHYPERTENSIVE AGENTS IN PATIENTS WITH ARTERIAL HYPERTENSION, CONCOMITANT TYPE 2 DIABETES MELLITUS AND OBESITY (LITERATURE REVIEW AND OWN DATA)
DOI:
https://doi.org/10.31618/ESSA.2782-1994.2021.2.68.21Keywords:
type 2 diabetes mellitus, arterial hypertension, obesity, treatment, ramipril, telmisartanAbstract
Treatment of patients with arterial hypertension with diabetes and obesity requires taking into account the individual risk of complications and the use of appropriate differentiated tactics, and therefore the appointment of complex treatment with drugs that inhibit excessive activation of the renin-angiotensin-aldosterone system, in particular angiotensin converting enzyme inhibitors and angiotensin II receptor blockers, is the most appropriate and justified. Thus, a comparative analysis of the use of various treatment regimens in patients with arterial hypertension, concomitant type 2 diabetes mellitus and obesity was carried out using the angiotensinconverting enzyme inhibitor ramipril and the angiotensin II receptor blocker telmisartan. The inclusion of ramipril or telmisartan in standard therapy has been shown to have a positive effect on the structural and functional parameters of the left ventricle and ejection fractions. Also, at the same time, the neutral effect of these drugs on carbohydrate and improvement of some components of lipid metabolism in the examined category of patients was determined.
References
Mankovskij B. N. Rasprostranennost arterialnoj gipertenzii i kontrol AD u bolnyh SD 2 tipa. Liki Ukrayini. 2011. № 6 (152). S. 17-18.
Cowie C. C. Diabetes Diagnosis and Control: Missed Opportunities to Improve Health : The 2018 Kelly West Award Lecture. Diabetes Care. 2019. Vol. 42 (6). P. 994‐1004. https://doi.org/10.2337/dci18-0047.
Nowakowska M., Zghebi S. S., Ashcroft D.M., et al. The comorbidity burden of type 2 diabetes mellitus: patterns, clusters and predictions from a large English primary care cohort. BMC Med. 2020. Vol. 18 (1). P. 22. DOI:10.1186/s12916-019-1373-y.
Demidova T. Yu., Kislyak O. A. Osobennosti techeniya i lechenie arterialnoj gipertenzii u pacientov s saharnym diabetom 2 tipa. Racionalnaya Farmakoterapiya v Kardiologii 2020. № 16 (4)yu S. 623-634. https://doi.org/10.20996/1819-64462020-08-02.
Bojcov S. A., Balanova Yu. A., Shalnova S. A., Deev A. D. i dr. Arterialnaya gipertoniya sredi lic 25-64 let: rasprostranennost, osvedomlennost, lechenie i kontrol. Po materialam issledovaniya ESSE.
Kardiovaskulyarnaya terapiya i profilaktika. 2014. № 4. C. 4-14. https://doi.org/org/10.15829/1728-8800-2014-4-4-14.
Stacenko M. E., Derevyanchenko M. V. Patogeneticheskij vklad insulinorezistentnosti v razvitie remodelirovaniya serdca u bolnyh arterialnoj gipertenziej v sochetanii s ozhireniem, saharnym diabetom 2 tipa. Rossijskij kardiologicheskij zhurnal. 2020. № 25 (4). S. 3752. https://doi.org/10.15829/1560-4071-2020-3752
Bassand J. P., Accetta G., Mahmeed W. A. et al. Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. PLoS One. 2018. Vol. 13 (1). P. 191-195. https://doi.org/10.1371/journal.pone.0191592.
American Diabetes Association: Clinical practice recommendations 2019. Diabetes Care. 2019. Vol. 29 (1). P. 1-85.
Molotyagin D. G. Efektivnist zastosuvannya riznih shem likuvannya u hvorih na ishemichnu hvorobu sercya ta arterialnu gipertenziyu na tli cukrovogo diabetu 2 tipu. Ukrayinskij zhurnal medicini, biologiyi ta sportu. 2020. Tom 5,
№ 3 (25). S. 208-214. DOI: 10.26693/jmbs05.03.208 10. U.K. Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type II diabetes: UKPDS 39. Br Med J. 1998. Vol. 317. P. 713-20.
Hanson L., Zanchetti A., Carruthers S. G., et al. Effects of intensive blood pressure lowering and lowdose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998. Vol. 351. P. 1755-62. https://doi.org/10.1016/s0140-6736(98)04311-6.
Guidelines on treatment of patients with arterial hypertension comorbid with metabolic disorders and diabetes mellitus type 2. Systemic Hypertension. 2020. Vol. 17 (1). P. 7-45.https://doi.org/10.26442/2075082X.2020.1.200051.
Williams B., Mancia G., Spiering W. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J. Hypertens. 2018. Vol. 36 (10). P. 1953-2041. https://doi.org/10.1093/eurheartj/ehy339.
Chazova I. E., Zhernakova Yu. V. Klinicheskie rekomendacii. Diagnostika i lechenie arterialnoj gipertonii. Sistemnye gipertenzii. 2019. № 16 (1). S. 6-31. https://doi.org/10.26442/2075082X.2019.1.190179 15. Lip G. Y. H., Coca A., Kahan T. et al. Hypertension and cardiac arrhythmias: executive summary of a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), AsiaPacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE). Eur Heart J Cardiovasc Pharmacother. 2017. Vol. 3. P. 235 250.https://doi.org/10.1093/ehjcvp/pvx019.
Grant P. Cosentino F. The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: New features and the ‘Ten Commandments’ of the 2019 Guidelines are discussed by Professor Peter J. Grant and Professor Francesco
Cosentino, the Task Force chairmen. Eur Heart J. 2019. Vol. 40 (39). P. 3215-3217. https://doi.org/10.1093/eurheartj/ehz687.
2019 ESC Guidelines on diabetes, prediabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020. Vol. 41(2). P. 255-323. https://doi.org/10.1093/eurheartj/ehz486
Unger T., Borghi C., Charchar F., Nadia A. et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020. Vol. 75. P. 1334-1357. https://doi.org/10.1161
Whelton P. K., Carey R. M., Aronow W. S. et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/AS PC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 2018. Vol. 71. P. e127-248. https://doi.org/10.1161/HYP.0000000000000065.
Sakamoto M., Matsutani D., Kayama Y. Possibility of a New Therapeutic Strategy for Left Ventricular Dysfunction in Type 2 Diabetes. J Clin Med Res. 2018. Vol. 10 (11). P. 799-805. DOI:10.14740/jocmr3584w.
Huang R., Feng Y., Wang Y. et al. Comparative Efficacy and Safety of Antihypertensive Agents for Adult Diabetic Patients with Microalbuminuric Kidney Disease: A Network MetaAnalysis. PLoS One. 2017. Vol. 12. P. e0168582.
Hsu F., Lin F., Ou H., et al. Renoprotective Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Diabetic Patients with Proteinuria. Kidney Blood Press Res. 2017. Vol. 42. P. 358-368. https://doi.org/10.1159/000477946.
Wald D. S., Law M., Morris J. K. et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from
trials. Am J Med. 2009. Vol. 122. P. 290-300.
Ettehad D., Emdin C. A., Kiran A. et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and metaanalysis. Lancet. 2016. Vol. 387. P. 957-967.
Thomopoulos C., Parati G., Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs – overview and meta-analyses. J Hypertens. 2015. Vol. 33. P. 1321-1341.
Oliver E., Mayor F. Jr., D'Ocon P. Betablockers: Historical Perspective and Mechanisms of Action. Rev Esp Cardiol (Engl Ed). 2019. Vol. 72 (10). P. 853 862.https://doi.org/ 10.1016/j.rec.2019.04.006.
Sinagra G., Corra U., Contini M. et al. Choosing among b-blockers in heart failure patients according to b-receptors' location and functions in the cardiopulmonary system. Pharmacol Res. 2020. Vol. 156. P. 104785. https://doi.org/10.1016/j.phrs.2020.104785.
McKeever R. G., Hamilton R. J. Calcium Channel Blockers. 2020 Jul 10. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan – . PMID: 29494080.
Smith D. K., Lennon R. P., Carlsgaard P. B. Managing Hypertension Using Combination Therapy. Am Fam Physician. 2020. Vol. 101 (6). P. 341-349.
Taylor B. N., Cassagnol M. Alpha Adrenergic Receptors. 2020 Nov 4. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan– . PMID: 30969652.
Pongpanich P., Pitakpaiboonkul P., Takkavatakarn K. et al. The benefits of angiotensinconverting enzyme inhibitors/angiotensin II receptor blockers combined with calcium channel blockers on metabolic, renal, and cardiovascular outcomes in hypertensive patients: a meta-analysis. International Urology and Nephrology. 2018 https://doi.org/10.1007/s11255018-1991-x.
Kario K., Tomitani N., Kanegae H., et al. Comparative Effects of an Angiotensin II Receptor Blocker (ARB)/Diuretic vs. ARB/Calcium-Channel
Blocker Combination on Uncontrolled Nocturnal Hypertension Evaluated by Information and Communication Technology-Based Nocturnal Home Blood Pressure Monitoring - The NOCTURNE Study. UDK 618.141–006.36–073.432.19 Circ J. 2017. Vol. 81 (7). P. 948‐957. https://doi.org/10.1253/circj.CJ-17- 0109.
Bousquet P., Hudson A., Garcia-Sevilla J. A. et al. Imidazoline Receptor System: The Past, the Present, and the Future. Pharmacol Rev. 2020. Vol. 72
(1). P. 50-79. https://doi.org/10.1124/pr.118.016311. PMID: 31819014.
Bousquet P., Hudson A., Carcia-Sevilla J. et al. Imidazoline Receptor System: The Past, the Present, and the Future. Pharmacological Reviews. 2020. Vol.
P. 50-79. https://doi.org/10.1124/pr.118.016311.
Korolyuk O. Ya. Poyednana blokada reninangiotenzin-aldosteronovoyi sistemi: za i proti. Zdorov’ya Ukrayini 21 storichchya. 2019. № 23 (468). S. 15-16.
Swedberg K., Kjekshus J., Snapinn S. Longterm survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I. Eur Heart J. 1999. Vol. 20 (2). P. 136-139. https://doi.org/10.1053/euhj.1998.1098. PMID: 10099910.
Nauman D., Greenberg B. Studies of Left
Ventricular Dysfunction (SOLVD). Am J Geriatr Cardiol. 1993. Vol. 2 (1). P. 28-36. PMID: 11416282.
Milicic D. ACE-inhibitori i antagonisti receptora za angiotenzin II u akutnom koronarnom sindromu [ACE inhibitors and angiotensin II receptor antagonists in acute coronary syndrome]. Acta Med Croatica. 2004. Vol. 58 (2). P. 129-134. Croatian.
PMID: 15208798.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
CC BY-ND
A work licensed in this way allows the following:
1. The freedom to use and perform the work: The licensee must be allowed to make any use, private or public, of the work.
2. The freedom to study the work and apply the information: The licensee must be allowed to examine the work and to use the knowledge gained from the work in any way. The license may not, for example, restrict "reverse engineering."
2. The freedom to redistribute copies: Copies may be sold, swapped or given away for free, in the same form as the original.
